<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32157143</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1&#x3b4; kinase inhibitor treatment.</ArticleTitle><Pagination><StartPage>4449</StartPage><MedlinePgn>4449</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4449</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-61265-y</ELocationID><Abstract><AbstractText>Pathogenesis of amyotrophic lateral sclerosis (ALS), a devastating disease where no treatment exists, involves the compartmentalization of the nuclear protein TDP-43 (TAR DNA-binding protein 43) in the cytoplasm which is promoted by its aberrant phosphorylation and others posttranslational modifications. Recently, it was reported that CK-1&#x3b4; (protein casein kinase-1&#x3b4;) is able to phosphorylate TDP-43. Here, the preclinical efficacy of a benzothiazole-based CK-1&#x3b4; inhibitor IGS-2.7, both in a TDP-43 (A315T) transgenic mouse and in a human cell-based model of ALS, is shown. Treatment with IGS-2.7 produces a significant preservation of motor neurons in the anterior horn at lumbar level, a decrease in both astroglial and microglial reactivity in this area, and in TDP-43 phosphorylation in spinal cord samples. Furthermore, the recovery of TDP-43 homeostasis (phosphorylation and localization) in a human-based cell model from ALS patients after treatment with IGS-2.7 is also reported. Moreover, we have shown a trend to increase in CK-1&#x3b4; mRNA in spinal cord and significantly in frontal cortex of sALS cases. All these data show for the first time the in vivo modulation of TDP-43 toxicity by CK-1&#x3b4; inhibition with IGS-2.7, which may explain the benefits in the preservation of spinal motor neurons and point to the relevance of CK-1&#x3b4; inhibitors in a future disease-modifying treatment for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez-Gonz&#xe1;lez</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Cueto</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabezudo</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartolom&#xe9;</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9322-8933</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria Hospital 12 de Octubre (imas12), 28041, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andr&#xe9;s-Benito</LastName><ForeName>Pol</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge University Hospital, IDIBELL (Bellvitge Biomedical Research Centre), Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Isidro</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9888-8754</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge University Hospital, IDIBELL (Bellvitge Biomedical Research Centre), Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Requero</LastName><ForeName>&#xc1;ngeles</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ruiz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2707-8110</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain. ana.martinez@csic.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. ana.martinez@csic.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6260-3777</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain. elagofem@ucm.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain. elagofem@ucm.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. elagofem@ucm.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048148">Casein Kinase Idelta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048148" MajorTopicYN="N">Casein Kinase Idelta</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32157143</ArticleId><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-61265-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-61265-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hergesheimer RC, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo, V. et al. TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chem Neurosci.10(3), 1183&#x2013;1196 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30785719</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Griffiths TD. Limbic-predominant age-related TDP-43 encephalopathy (LATE) Brain. 2019;142:e42. doi: 10.1093/brain/awz184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz184</ArticleId><ArticleId IdType="pubmed">31243434</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, S. A., Gan, K. A., Dowell, J. A., Cairns, N. J. &amp; Gitcho, M. A. TDP-43 expression influences amyloid &#x3b2; plaque deposition and tau aggregation. Neurobiol. Dis.103, 154&#x2013;162 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5544914</ArticleId><ArticleId IdType="pubmed">28416393</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes &#xc1;CB, et al. Distinct Phospho-TDP-43 brain distribution in two cases of FTD, one associated with ALS. Dement. Neuropsychol. 2017;11:249&#x2013;254. doi: 10.1590/1980-57642016dn11-030006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1980-57642016dn11-030006</ArticleId><ArticleId IdType="pmc">PMC5674668</ArticleId><ArticleId IdType="pubmed">29213521</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko, N. F. et al. The Tau Tubulin Kinases TTBK1/2 Promote Accumulation of Pathological TDP-43. PLoS Genet. 10(12) :e1004803 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256087</ArticleId><ArticleId IdType="pubmed">25473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, et al. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann. Neurol. 2013;74:39&#x2013;52. doi: 10.1002/ana.23870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23870</ArticleId><ArticleId IdType="pmc">PMC3775949</ArticleId><ArticleId IdType="pubmed">23424178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1&#x3b4; triggers mislocalization and accumulation of TDP-43. J. Biol. Chem. 2016;291:5473&#x2013;5483. doi: 10.1074/jbc.M115.695379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.695379</ArticleId><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks, D. A., Cross, L. L., Williamson, R. &amp; Rattray, M. Endoplasmic Reticulum Stress Signalling Induces Casein Kinase 1-Dependent Formation of Cytosolic TDP-43 Inclusions in Motor Neuron-Like Cells. Neurochem. Res., 10.1007/s11064-019-02832-2 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260270</ArticleId><ArticleId IdType="pubmed">31280399</ArticleId></ArticleIdList></Reference><Reference><Citation>Krach F, et al. Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol. 2018;136:405&#x2013;423. doi: 10.1007/s00401-018-1870-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1870-7</ArticleId><ArticleId IdType="pmc">PMC6215775</ArticleId><ArticleId IdType="pubmed">29881994</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozza G, Pinna LA. Casein kinases as potential therapeutic targets. Expert Opin. Ther. Targets. 2016;20:319&#x2013;340. doi: 10.1517/14728222.2016.1091883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2016.1091883</ArticleId><ArticleId IdType="pubmed">26565594</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, J. et al. Elevation of casein kinase 1&#x3b5; associated with TDP&#x2010;43 and tau pathologies in Alzheimer&#x2019;s disease. Brain Pathol. 30(2), 283&#x2013;297 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31376192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;14. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. The Role of immune and inflammatory mechanisms in ALS. Curr. Mol. Med. 2011;11:246&#x2013;54. doi: 10.2174/156652411795243450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Alquezar C, et al. Targeting TDP-43 phosphorylation by Casein Kinase-1&#x3b4; inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol. Neurodegener. 2016;11:36. doi: 10.1186/s13024-016-0102-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0102-7</ArticleId><ArticleId IdType="pmc">PMC4852436</ArticleId><ArticleId IdType="pubmed">27138926</ArticleId></ArticleIdList></Reference><Reference><Citation>Posa, D. et al. Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. Molecular Neurobiology, 56(4), 2424&#x2013;2432 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30030753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Wu LS, Shen C-KKJ. TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol. Med. 2008;14:479&#x2013;485. doi: 10.1016/j.molmed.2008.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2008.09.001</ArticleId><ArticleId IdType="pubmed">18929508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, et al. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum. Mol. Genet. 2010;19:3206&#x2013;3218. doi: 10.1093/hmg/ddq230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq230</ArticleId><ArticleId IdType="pmc">PMC2908471</ArticleId><ArticleId IdType="pubmed">20530643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2010;19:671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto Y, et al. Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J. Biol. Chem. 2010;285:608&#x2013;619. doi: 10.1074/jbc.M109.022012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.022012</ArticleId><ArticleId IdType="pmc">PMC2804209</ArticleId><ArticleId IdType="pubmed">19887443</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH. TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. FEBS J. 2011;278:3539&#x2013;3549. doi: 10.1111/j.1742-4658.2011.08256.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2011.08256.x</ArticleId><ArticleId IdType="pmc">PMC3177991</ArticleId><ArticleId IdType="pubmed">21777387</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteras N, Alqu&#xe9;zar C, de la Encarnaci&#xf3;n A, Mart&#xed;n-Requero &#xc1;. Lymphocytes in Alzheimer&#x2019;s disease pathology: Altered signaling pathways. Curr. Alzheimer Res. 2016;13:439&#x2013;49. doi: 10.2174/1567205013666151116124912.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666151116124912</ArticleId><ArticleId IdType="pubmed">26567747</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, P. et al. Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D). Gene715:144005 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31376410</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandon EP, et al. Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice. J. Neurosci. 2003;23:539&#x2013;49. doi: 10.1523/JNEUROSCI.23-02-00539.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-02-00539.2003</ArticleId><ArticleId IdType="pmc">PMC6741871</ArticleId><ArticleId IdType="pubmed">12533614</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Garcia JA, et al. Biological and Pharmacological Characterization of Benzothiazole-Based CK-1&#x3b4; Inhibitors in Models of Parkinson&#x2019;s Disease. ACS omega. 2017;2:5215&#x2013;5220. doi: 10.1021/acsomega.7b00869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.7b00869</ArticleId><ArticleId IdType="pmc">PMC6044573</ArticleId><ArticleId IdType="pubmed">30023743</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado IG, et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J. Med. Chem. 2014;57:2755&#x2013;2772. doi: 10.1021/jm500065f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm500065f</ArticleId><ArticleId IdType="pmc">PMC3969104</ArticleId><ArticleId IdType="pubmed">24592867</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Porras F, et al. Targeting glial cannabinoid CB 2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2019;176:1585&#x2013;1600. doi: 10.1111/bph.14216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14216</ArticleId><ArticleId IdType="pmc">PMC6487601</ArticleId><ArticleId IdType="pubmed">29574689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarreta D, Urcelay E, Parrilla R, Ayuso MS. Distinct pH homeostatic features in lymphoblasts from Alzheimer&#x2019;s disease patients. Ann. Neurol. 1998;44:216&#x2013;222. doi: 10.1002/ana.410440212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440212</ArticleId><ArticleId IdType="pubmed">9708544</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;9. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Porras F, et al. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of Neuroimmune Pharmacology. 2015;10:233&#x2013;244. doi: 10.1007/s11481-015-9602-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-015-9602-4</ArticleId><ArticleId IdType="pubmed">25819934</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteras N, et al. Calmodulin levels in blood cells as a potential biomarker of Alzheimer&#x2019;s disease. Alzheimers. Res. Ther. 2013;5:55. doi: 10.1186/alzrt219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt219</ArticleId><ArticleId IdType="pmc">PMC3978675</ArticleId><ArticleId IdType="pubmed">24499616</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Moreno J, Aso E, Povedano M, Ferrer I. Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration. Aging (Albany. NY). 2017;9:823&#x2013;851. doi: 10.18632/aging.101195.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101195</ArticleId><ArticleId IdType="pmc">PMC5391234</ArticleId><ArticleId IdType="pubmed">28283675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>